{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:44Z","timestamp":1792282664154,"version":"4.4.0"},"reference-count":95,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombin plays a central role in hemostasis, serving as both the primary enzyme driving fibrin formation and the central regulator of anticoagulant pathways. Routine coagulation assays, such as prothrombin time and activated partial thromboplastin time, capture only a limited fraction of thrombin's role, overlooking inhibitory pathways and downstream regulation. Thrombin generation assays (TGAs) provide a global view of coagulation, measuring both formation and inhibition of thrombin over time. TGAs generate thrombin activity curves, from which parameters such as lag time, peak thrombin, time to peak, velocity index, and endogenous thrombin potential are derived. These parameters reflect hyper- or hypocoagulability and have been linked to clinical outcomes. Applications include monitoring anticoagulant therapy and reversal strategies, predicting venous thromboembolism recurrence, assessing thrombotic risk in cardiovascular disease and antiphospholipid syndrome, and stratifying bleeding risk in bleeding disorders. TGAs can also evaluate the efficacy of bypassing agents and novel hemostatic drugs in ex vivo settings. Barriers include technical complexity, preanalytical variability, and lack of standardization across laboratories. TGAs provide a global assessment of coagulation, demonstrating added value in both hyper- and hypocoagulable states. While most data remain research-based, growing evidence supports their utility in thrombotic risk prediction and bleeding risk assessment. Wider adoption in clinical practice will depend on assay standardization, validation in multicenter studies, and integration into clinical decision-making pathways.<\/jats:p>","DOI":"10.1055\/a-2811-3096","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:55:06Z","timestamp":1771030506000},"page":"448-459","source":"Crossref","is-referenced-by-count":1,"title":["Thrombin Generation Assays in Clinical Hemostasis: From Mechanistic Insights to Clinical Applications"],"prefix":"10.1055","volume":"52","author":[{"given":"Joris","family":"Godelaine","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Van Laer","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Continuing education course #2: Current understanding of hemostasis","volume":"39","author":"A J Gale","year":"2011","journal-title":"Toxicol Pathol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: A narrative review","volume":"7","author":"R F Sidonio Jr","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"K G Mann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1055\/s-0038-1649638","article-title":"Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential","volume":"70","author":"H C Hemker","year":"1993","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MBC.0000000000001170","article-title":"Thrombin generation assay: The present and the future","volume":"34","author":"Y Wu","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine","volume":"19","author":"F Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1055\/a-1450-8300","article-title":"Added value of blood cells in thrombin generation testing","volume":"121","author":"J Wan","year":"2021","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"A Tripodi","year":"2016","journal-title":"Clin Chem"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2141.2009.07833.x","article-title":"Acquired coagulation disorders: revisited using global coagulation\/anticoagulation testing","volume":"147","author":"A Tripodi","year":"2009","journal-title":"Br J Haematol"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/j.thromres.2012.04.002","article-title":"Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer","volume":"130","author":"B H Shirts","year":"2012","journal-title":"Thromb Res"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/jth.15538","article-title":"Clinical use of thrombin generation assays","volume":"19","author":"N B Binder","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref12","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: A practical guide to common clinical challenges","volume":"9","author":"A Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/rth2.12044","article-title":"Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay","volume":"1","author":"R Artang","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1177\/1076029618802364","article-title":"Laboratory assessment of the anticoagulant activity of apixaban in patients with nonvalvular atrial fibrillation","volume":"24","author":"E Kyriakou","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"05","key":"ref15","first-page":"989","article-title":"Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban","volume":"111","author":"R Herrmann","year":"2014","journal-title":"Thromb Haemost"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"717939","DOI":"10.3389\/fcvm.2021.717939","article-title":"Automated thrombin generation assay for rivaroxaban, apixaban, and edoxaban measurements","volume":"8","author":"T Meihandoest","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12959-017-0129-1","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor","volume":"15","author":"N H Schultz","year":"2017","journal-title":"Thromb J"},{"issue":"25","key":"ref18","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"D M Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"E S Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/bja\/aew259","article-title":"Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay","volume":"117","author":"B Schenk","year":"2016","journal-title":"Br J Anaesth"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"e12699","DOI":"10.1002\/rth2.12699","article-title":"Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro","volume":"6","author":"H JM Brinkman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: A randomized three-period crossover study","volume":"15","author":"Y Song","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/JBM.S121550","article-title":"Reversing factor Xa inhibitors - clinical utility of andexanet alfa","volume":"8","author":"S Kaatz","year":"2017","journal-title":"J Blood Med"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"e0199900","DOI":"10.1371\/journal.pone.0199900","article-title":"Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment","volume":"13","author":"A N Balandina","year":"2018","journal-title":"PLoS ONE"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.thromres.2010.07.015","article-title":"Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults","volume":"126","author":"M M Samama","year":"2010","journal-title":"Thromb Res"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/j.1538-7836.2007.02753.x","article-title":"Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants","volume":"5","author":"M M Samama","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1055\/s-0038-1672183","article-title":"Calibrated automated thrombinography (CAT), a tool to identify patients at risk of bleeding during anticoagulant therapy: A systematic review","volume":"2","author":"S Zwaveling","year":"2018","journal-title":"TH Open"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"679934","DOI":"10.3389\/fcvm.2021.679934","article-title":"Thrombin generation as a method to identify the risk of bleeding in high clinical-risk patients using dual antiplatelet therapy","volume":"8","author":"C PDM de Breet","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1160\/TH03-07-0483","article-title":"Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood","volume":"91","author":"G T Gerotziafas","year":"2004","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MBC.0000000000000887","article-title":"Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: A comparison between 3-factor and 4-factor prothrombin complex concentrates","volume":"31","author":"L Spiezia","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"101356","DOI":"10.1016\/j.jacbts.2025.101356","article-title":"Preclinical efficacy of a hemostatic agent in overcoming dual antiplatelet therapy","volume":"10","author":"E Efimenko","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jama.299.11.1306","article-title":"Gene variants associated with deep vein thrombosis","volume":"299","author":"I D Bezemer","year":"2008","journal-title":"JAMA"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1086\/316903","article-title":"Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic analysis of idiopathic thrombophilia","volume":"67","author":"J C Souto","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.3390\/ijms24043169","article-title":"A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology","volume":"24","author":"D Pastori","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jama.296.4.397","article-title":"Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation","volume":"296","author":"G Hron","year":"2006","journal-title":"JAMA"},{"issue":"15","key":"ref36","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"C Ay","year":"2011","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1538-7836.2007.02448.x","article-title":"Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia","volume":"5","author":"E Castoldi","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0043-1775856","article-title":"Thrombin generation markers as predictors of cancer-associated venous thromboembolism: A systematic review","volume":"50","author":"T Gyldenholm","year":"2024","journal-title":"Semin Thromb Hemost"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"109384","DOI":"10.1016\/j.thromres.2025.109384","article-title":"Thrombin generation assay in venous thromboembolism: A scoping review","volume":"252","author":"M EM Souza","year":"2025","journal-title":"Thromb Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"109454","DOI":"10.1016\/j.thromres.2025.109454","article-title":"Clinical utility of thrombin generation using ST-Genesia\u00ae in patients with hereditary and acquired thrombophilia: A cross-sectional study","volume":"254","author":"L Caspary","year":"2025","journal-title":"Thromb Res"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.jtha.2025.04.026","article-title":"Implementation and clinical utility of multigene panels for bleeding, platelet, and thrombotic disorders","volume":"23","author":"R Ramanan","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jtha.2022.12.007","article-title":"Clinical application of multigene panel testing for bleeding, thrombotic, and platelet disorders: A 3-year Belgian experience","volume":"21","author":"C Van Laer","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"17","key":"ref43","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2024026454","article-title":"Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis","volume":"145","author":"C Van Laer","year":"2025","journal-title":"Blood"},{"issue":"09","key":"ref44","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/j.jtha.2025.05.016","article-title":"Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism","volume":"23","author":"C Van Laer","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1373\/clinchem.2005.063339","article-title":"Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency","volume":"52","author":"N H\u00e9zard","year":"2006","journal-title":"Clin Chem"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11926-024-01140-1","article-title":"Thrombin generation assay in antiphospholipid antibodies positive subjects as a personalized thrombotic risk assessment: State of the art and perspectives","volume":"26","author":"T Foret","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0037-1613433","article-title":"Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants","volume":"89","author":"V Regnault","year":"2003","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1160\/TH08-06-0393","article-title":"Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography","volume":"101","author":"K Devreese","year":"2009","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.3390\/biomedicines11123329","article-title":"Determining thrombogenicity: Using a modified thrombin generation assay to detect the level of thrombotic event risk in lupus anticoagulant-positive patients","volume":"11","author":"P Brad\u00e1\u010dov\u00e1","year":"2023","journal-title":"Biomedicines"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"e005489","DOI":"10.1136\/rmdopen-2025-005489","article-title":"Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome","volume":"11","author":"C Yelnik","year":"2025","journal-title":"RMD Open"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/bloodadvances.2023011938","article-title":"A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation","volume":"8","author":"R MW de Laat-Kremers","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/bloodadvances.2018018036","article-title":"Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin","volume":"2","author":"R MW Kremers","year":"2018","journal-title":"Blood Adv"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.thromres.2016.09.020","article-title":"Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention","volume":"147","author":"M Attanasio","year":"2016","journal-title":"Thromb Res"},{"issue":"14","key":"ref54","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/heartjnl-2014-306685","article-title":"The hypercoagulable profile of patients with stent thrombosis","volume":"101","author":"R Loeffen","year":"2015","journal-title":"Heart"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11239-020-02066-y","article-title":"Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation","volume":"50","author":"C Yip","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1160\/TH07-07-0443","article-title":"Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test","volume":"99","author":"J Orbe","year":"2008","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref57","first-page":"553","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system","volume":"96","author":"H C Hemker","year":"2006","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref58","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation","volume":"18","author":"L LFG Valke","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"E Santagostino","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/j.thromres.2013.04.004","article-title":"Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics","volume":"131","author":"I D Tarandovskiy","year":"2013","journal-title":"Thromb Res"},{"issue":"25","key":"ref61","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Y Dargaud","year":"2010","journal-title":"Blood"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1076029619836171","DOI":"10.1177\/1076029619836171","article-title":"Evaluation of global hemostatic assays in response to factor VIII inhibitors","volume":"25","author":"P Chen","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"C Negrier","year":"2019","journal-title":"Blood Rev"},{"issue":"05","key":"ref64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/bloodadvances.2024013900","article-title":"Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B","volume":"9","author":"S W Pipe","year":"2025","journal-title":"Blood Adv"},{"key":"ref65","first-page":"379","article-title":"Marstacimab for the treatment of hemophilia A or B","volume":"19","author":"J Mahlangu","year":"2025","journal-title":"Biologics"},{"issue":"12","key":"ref66","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): A prospective, multicentre, open-label, randomised, phase 3a trial","volume":"11","author":"P Chowdary","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3324\/haematol.11460","article-title":"Thrombin-generating capacity in patients with von Willebrand's disease","volume":"92","author":"L Rugeri","year":"2007","journal-title":"Haematologica"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Y Dargaud","year":"2018","journal-title":"Haematologica"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2040620719860025","DOI":"10.1177\/2040620719860025","article-title":"Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays","volume":"10","author":"H Kizilocak","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1749-8090-8-154","article-title":"Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: A research article","volume":"8","author":"Y Bosch","year":"2013","journal-title":"J Cardiothorac Surg"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1538-7836.2010.04146.x","article-title":"Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding","volume":"9","author":"M Coakley","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12630-021-02165-1","article-title":"The association of thrombin generation with bleeding outcomes in cardiac surgery: A prospective observational study","volume":"69","author":"J Bartoszko","year":"2022","journal-title":"Can J Anaesth"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/10760296221123310","article-title":"Assessment of rotational thromboelastometry and thrombin generation assay to identify risk of high blood loss and re-operation after cardiac surgery","volume":"28","author":"D Jeong","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"03","key":"ref74","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.thromres.2013.12.017","article-title":"Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery","volume":"133","author":"Y P Bosch","year":"2014","journal-title":"Thromb Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2022.02.011","article-title":"Coagulation activation during extracorporeal membrane oxygenation (ECMO)","volume":"211","author":"W L Chandler","year":"2022","journal-title":"Thromb Res"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"1155496","DOI":"10.3389\/fmed.2023.1155496","article-title":"The endogenous thrombin potential in patients with left ventricular assist device or heart transplant","volume":"10","author":"A Schlagenhauf","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"ref77","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1055\/a-2521-0923","article-title":"Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: A nested case-control study","volume":"125","author":"J R Shaw","year":"2025","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref78","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/jth.12012","article-title":"Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method","volume":"10","author":"R Loeffen","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref79","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Y Dargaud","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref80","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"M Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref81","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"H C Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"109045","DOI":"10.1016\/j.thromres.2024.109045","article-title":"Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: A comprehensive assessment","volume":"240","author":"B Haisma","year":"2024","journal-title":"Thromb Res"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/rth2.12048","article-title":"A review of commercially available thrombin generation assays","volume":"2","author":"J Kintigh","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MBC.0000000000000898","article-title":"Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients","volume":"31","author":"I V Gribkova","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1008410","DOI":"10.3389\/fcvm.2022.1008410","article-title":"Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood","volume":"9","author":"S Konrath","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"03","key":"ref86","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jtha.2022.11.029","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","volume":"21","author":"J R Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12917-021-03058-7","article-title":"A pilot study evaluating the Calibrated Automated Thrombogram assay and application of plasma-thromboelastography for detection of hemostatic aberrations in horses with gastrointestinal disease","volume":"17","author":"M L Honor\u00e9","year":"2021","journal-title":"BMC Vet Res"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.thromres.2014.11.037","article-title":"Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism","volume":"135","author":"D RJ Arachchillage","year":"2015","journal-title":"Thromb Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"769187","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: Review and perspective to mitigate the risk","volume":"12","author":"L Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1160\/TH05-10-0685","article-title":"Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT)","volume":"95","author":"H Haidl","year":"2006","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref91","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jth.14863","article-title":"Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey","volume":"18","author":"R MW de Laat-Kremers","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/rth2.12455","article-title":"ST Genesia reference values of 117 healthy donors measured with STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen reagents","volume":"5","author":"M Ninivaggi","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"e12654","DOI":"10.1002\/rth2.12654","article-title":"Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between-subject variation","volume":"6","author":"S R Kristensen","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref94","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2007.06738.x","article-title":"Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence","volume":"138","author":"A van Hylckama Vlieg","year":"2007","journal-title":"Br J Haematol"},{"issue":"09","key":"ref95","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jth.13043","article-title":"The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: Results of the THE-VTE study","volume":"13","author":"A van Hylckama Vlieg","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2811-3096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:52:39Z","timestamp":1778021559000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2811-3096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":95,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2811-3096","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,13]]},"published":{"date-parts":[[2026,2,13]]}}}